TRIB

Trinity Biotech plc American Depositary Shares

TRIB
Closed
$0.38
Closed
-(-)

At close

Financial advisor consultation illustration
Get professional financial guidance

Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply

About

Trinity Biotech Plc engages in the development, manufacture, and marketing of medical diagnostic products for the clinical laboratory and point-of-care segments of the diagnostic market. The firm develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market. The products are used to detect infectious diseases and to quantify the level of Hemoglobin A1c and other chemical parameters in serum, plasma and whole blood, and the Company intends to develop a range of biosensor devices and related services, starting with a continuous glucose monitoring product. Its TrinScreen Human Immunodeficiency Virus (HIV) rapid point-of-care test is a high-quality, single-use immunoassays to aid in the diagnosis of HIV. The Uni-Gold range of rapid point-of-care test devices consist of high-quality, single-use immunoassays to aid in the diagnosis of HIV.
Country

IE

CEO

Mr. John Gillard

IPO date

1992

Employees

401

ISIN

US8964385046

Key stats

Open

$0.38

Volume

323.84K

Market cap

$7.56M

Prev. close

$0.39

Impl / hst vl

-

Open interest

$0.00

$0.36

Day’s Range

$0.39

$0.31

52W Range

$0.96

Valuation

33
Valuation score
Overvalued
P/E
-
P/S
0.13
P/B
-
Current ratio
1.03
Debt / Equity
-
ROE
-
Gross margin
45.19%
Income growth
-13.94%
FCF growth
-63.71

Analysts estimates

Consensus rating
Strong buy

The average rating from top 3 analysts indicates that stock may significantly outperform the market

Str. Sell
Sell
Hold
Buy
Str. Buy
Avg. price target
$3.06
The top 3 analysts forecasts that 12-month price may increase by 705.26%, with a low of $3.03 and a high of $3.15
$3.03
Low
$3.06
Avg
$3.15
High
Current price

Earnings

Q3 ‘25 revenue
$14.31M
Q3 ‘25 net income
-$5.14M
Revenue
Net income
Previous EPS
-
Estimate EPS
-$0.17
Actual EPS
Estimate EPS
Financial advisor consultation illustration
Get professional financial guidance

Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply